Deb, G., Rondán, A. B., Burnett, K., Olmedo, H., Acosta, P. L., Bernal, A. I. M., Nguyen, S., Castiglioni, P., Coberly, S., Guarinos, C., Groocock, L., Narla, R. K., Lopez-Girona, A., Carrancio, S., Bence, N. (2025). BMS-986458, a first-in-class, highly selective, and potent ligand-directed degrader (LDD) of B-cell lymphoma 6 (BCL6) combined with T-cell engagers (TCEs) demonstrates preclinical synergistic antitumor efficacy for the treatment of B-cell non-Hodgkin lymphoma (NHL). Blood. https://doi.org/10.1182/blood-2025-5090